EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Old Drug, New Opportunity: Drug Repurposing in Cardiovascular Diseases

Xiuyi Ou, Sa Liu, Pengcheng Sun, Yuanying Yang, Yangchun Xie iD, Bikui Zhang, Yuanjian Li, Wenqun Li iD, Taoli Sun

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70272 ↗

At a glance

Übersichtsarbeit in Chemical Biology & Drug Design, 2026. Written by Xiuyi Ou and 8 co-authors. Institution: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Major MEDLINE topics: Drug Repositioning, Cardiovascular Diseases, Cardiovascular Agents. Cited 1 times so far (Crossref); 175 references. Funded by: National Natural Scientific Foundation of China, Hunan Provincial Natural Scientific Foundation, Hunan Provincial Education Department Funding Research Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cardiovascular disease (CVD) remains the major burden on global health. However, the development and approval of novel CVD therapeutics have declined, largely due to their protracted timelines and prohibitive costs. Drug repurposing has emerged as a promising strategy to overcome these limitations by leveraging data from approved drugs, thereby reducing both developmental costs and time‐to‐application. In this review, we systematically evaluate the repurposing potential of currently available drugs for CVD, elucidating their potential mechanisms, efficacy, and safety profiles. Furthermore, we discuss methodologies that facilitate the identification of promising repurposing candidates. These approaches may yield safer, more efficacious, and cost‐effective alternatives for CVD, bridging the gap between clinical needs and drug development pipelines. We also address the translational and commercial barriers specific to CVD drug repurposing and propose that integrating precision medicine, artificial intelligence driven discovery, and collaborative frameworks represents a viable strategy to overcome these hurdles.

Subjects

MeSH terms (MEDLINE)

Drug RepositioningCardiovascular DiseasesCardiovascular AgentsHumansDrug DiscoveryAnimals

Author keywords

cardiovascular diseasesclinical translationdrug discoverydrug repurposingdrug targets

Substances

Cardiovascular Agents

Authors and institutions

  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Medicated Food and Dietotherapy Reasearch Institute, Hunan Academy of Chinese Medicine, Changsha, Hunan, China.
  • Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, China.

ORCID profiles: Yangchun Xie, Wenqun Li

Funding

  • National Natural Scientific Foundation of China
  • Hunan Provincial Natural Scientific Foundation
  • Hunan Provincial Education Department Funding Research Project
  • Scientific Research Project of Hunan Provincial Health Commission

Cite

APA

Ou, X., Liu, S., Sun, P., Yang, Y., Xie, Y., Zhang, B., Li, Y., Li, W., & Sun, T. (2026). Old Drug, New Opportunity: Drug Repurposing in Cardiovascular Diseases. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70272

Vancouver

Ou X, Liu S, Sun P, Yang Y, Xie Y, Zhang B, et al. Old Drug, New Opportunity: Drug Repurposing in Cardiovascular Diseases. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70272

BibTeX
@article{Ou2026,
  author = {Ou, Xiuyi and Liu, Sa and Sun, Pengcheng and Yang, Yuanying and Xie, Yangchun and Zhang, Bikui and Li, Yuanjian and Li, Wenqun and Sun, Taoli},
  title = {Old Drug, New Opportunity: Drug Repurposing in Cardiovascular Diseases},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70272}
}
Start for free →